Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Effect of theophylline on histone deacetylase activity: enhancement of in-vitro glucocorticoid function in patients with COPD.

    Summary
    EudraCT number
    		 2005-003344-62
    Trial protocol
    		 GB  
    Global end of trial date
    29 Aug 2007

    Results information
    Results version number
    		 v1(current)
    This version publication date
    13 Nov 2019
    First version publication date
    13 Nov 2019
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    mitHDAC
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT00241631
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Imperial College London
    Sponsor organisation address
    South Kensingston Campus, London, United Kingdom, SW7 2AZ
    Public contact
    Prof Ian Adcock, Imperial College London, +44 20 7594 7840, ian.adcock@imperial.ac.uk
    Scientific contact
    Prof Ian Adcock, Imperial College London, +44 20 7594 7840, ian.adcock@imperial.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 Aug 2008
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    29 Aug 2007
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Aug 2007
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Does the addition of low dose theophylline (a drug already commonly used in Chronic Obstructive Lung Disease - COPD) restore the putative anti-inflammatory effects (measured from in-vitro samples taken by inducing sputum production) of inhaled steroids in patients with COPD?
    Protection of trial subjects
    None
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    03 Apr 2006
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 49
    Worldwide total number of subjects
    49
    EEA total number of subjects
    49
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    30
    From 65 to 84 years
    19
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Participants were recruited between April 2006 and August 2007.

    Pre-assignment
    Screening details
    		 Total of Forty-nine theophylline-naive (Global Initiative for Chronic Obstructive Lung Disease stage 2 or 3) patients with COPD were screened, 30 participants completed the study.

    Period 1
    Period 1 title
    Run-in
    Is this the baseline period?
    		 No
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 All participants
    Arm description
    		 -
    Arm type
    		 No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 1
    		All participants
    Started
    49
    Completed
    43
    Not completed
    6
         Physician decision
    6
    Period 2
    Period 2 title
    Phase 1
    Is this the baseline period?
    		 No
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Placebo
    Arm description
    		 Inhaled placebo capsule
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Inhalation vapour, tablet
    Routes of administration
    Inhalation use
    Dosage and administration details
    4 weeks

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    placebo theophylline capsules for 4 weeks

    Arm title
    		 Steroid
    Arm description
    		 Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline
    Arm type
    		 Experimental

    Investigational medicinal product name
    Fluticasone Propionate
    Investigational medicinal product code
    Other name
    Flovent
    Pharmaceutical forms
    Inhalation vapour, capsule
    Routes of administration
    Inhalation use
    Dosage and administration details
    500 ug bid for 4 weeks

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    placebo theophylline capsules

    Number of subjects in period 2
    		Placebo Steroid
    Started
    22
    21
    Completed
    14
    16
    Not completed
    8
    5
         Consent withdrawn by subject
    4
    4
         Sore throat
    1
    -
         Lost to follow-up
    3
    -
         Lack of efficacy
    -
    1
    Period 3
    Period 3 title
    Phase 2
    Is this the baseline period?
    		 Yes [1]
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Placebo
    Arm description
    		 Inhaled placebo plus oral slo-phylline capsule 250mg bid
    Arm type
    		 Placebo

    Investigational medicinal product name
    Theophylline
    Investigational medicinal product code
    Other name
    Slo-phyllin capsule
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    250 mg bid for 4 weeks

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Inhalation vapour, tablet
    Routes of administration
    Inhalation use
    Dosage and administration details
    4 weeks

    Arm title
    		 Steroid
    Arm description
    		 Inhaled Fluticasomne propionate 500mg bid plus oral slo-phylline capsule 250mg bid
    Arm type
    		 Experimental

    Investigational medicinal product name
    Theophylline
    Investigational medicinal product code
    Other name
    Slo-phyllin capsule
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    250 mg bid for 4 weeks

    Investigational medicinal product name
    Fluticasone Propionate
    Investigational medicinal product code
    Other name
    Flovent
    Pharmaceutical forms
    Inhalation vapour, capsule
    Routes of administration
    Inhalation use
    Dosage and administration details
    500 ug bid for 4 weeks

    Notes
    [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.
    Justification: Baseline period we reported participants they completed the study
    Number of subjects in period 3 [2]
    		Placebo Steroid
    Started
    14
    16
    Completed
    14
    16
    Notes
    [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Baseline period we reported participants they completed the study
    Period 4
    Period 4 title
    Wash out
    Is this the baseline period?
    		 No
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 All participants
    Arm description
    		 All participants between phase 1 and 2, no treatment
    Arm type
    		 No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 4
    		All participants
    Started
    30
    Completed
    30

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 Inhaled placebo plus oral slo-phylline capsule 250mg bid

    Reporting group title
    Steroid
    Reporting group description
    		 Inhaled Fluticasomne propionate 500mg bid plus oral slo-phylline capsule 250mg bid

    Reporting group values
    		 Placebo Steroid Total
    Number of subjects
    		 14 16 30
    Age categorical
    Units: Subjects
        In utero
    		 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0
        Newborns (0-27 days)
    		 0
        Infants and toddlers (28 days-23 months)
    		 0
        Children (2-11 years)
    		 0
        Adolescents (12-17 years)
    		 0
        Adults (18-64 years)
    		 0
        From 65-84 years
    		 0
        85 years and over
    		 0
    Age continuous
    Units: years
        geometric mean (standard deviation)
    		 61 ( 2.2 ) 69 ( 1.9 ) -
    Gender categorical
    Units: Subjects
        Female
    		 3 2 5
        Male
    		 11 14 25

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    All participants
    Reporting group description
    		 -
    Reporting group title
    Placebo
    Reporting group description
    		 Inhaled placebo capsule

    Reporting group title
    Steroid
    Reporting group description
    		 Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline
    Reporting group title
    Placebo
    Reporting group description
    		 Inhaled placebo plus oral slo-phylline capsule 250mg bid

    Reporting group title
    Steroid
    Reporting group description
    		 Inhaled Fluticasomne propionate 500mg bid plus oral slo-phylline capsule 250mg bid
    Reporting group title
    All participants
    Reporting group description
    		 All participants between phase 1 and 2, no treatment

    Primary: Sputum Inflammatory Cell Counts

    		 Close Top of page
    End point title
    		 Sputum Inflammatory Cell Counts
    End point description
    End point type
    Primary
    End point timeframe
    10 weeks
    End point values
    		 Placebo Steroid
    Number of subjects analysed
    14
    16
    Units: millions cells/ ml
        log mean (confidence interval 95%)
    5.42 (3.56 to 8.2)
    3.89 (2.6 to 5.76)
    Statistical analysis title
    		 Sputum Inflammatory Cell Counts
    Comparison groups
    Placebo v Steroid
    Number of subjects included in analysis
    30
    Analysis specification
    Post-hoc
    Analysis type
    		 superiority
    P-value
    		 = 0.012
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Interleukin 8 (IL8)

    		 Close Top of page
    End point title
    		 Interleukin 8 (IL8)
    End point description
    End point type
    Secondary
    End point timeframe
    10 weeks
    End point values
    		 Placebo Steroid
    Number of subjects analysed
    14
    16
    Units: ng/mL
        log mean (confidence interval 95%)
    33.3 (20 to 56)
    28.3 (19 to 42)
    Statistical analysis title
    		 IL 8
    Comparison groups
    Placebo v Steroid
    Number of subjects included in analysis
    30
    Analysis specification
    Post-hoc
    Analysis type
    		 superiority
    P-value
    		 < 0.05 [1]
    Method
    		 Mixed models analysis
    Confidence interval
    Notes
    [1] - calculated

    Secondary: Total sputum eosinophils

    		 Close Top of page
    End point title
    		 Total sputum eosinophils
    End point description
    End point type
    Secondary
    End point timeframe
    10 weeks
    End point values
    		 Placebo Steroid
    Number of subjects analysed
    14
    16
    Units: millions/mL
        log mean (confidence interval 95%)
    0.132 (0.09 to 0.2)
    0.053 (0.03 to 0.1)
    Statistical analysis title
    		 Total sputum eosinophils
    Comparison groups
    Steroid v Placebo
    Number of subjects included in analysis
    30
    Analysis specification
    Post-hoc
    Analysis type
    		 superiority
    P-value
    		 < 0.05 [2]
    Method
    		 Mixed models analysis
    Confidence interval
    Notes
    [2] - calculated

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    10 weeks
    Assessment type
    		 Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    10
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 Inhaled Theophylline placebo capsule, then placebo, then active Theophylline

    Reporting group title
    Steroid
    Reporting group description
    		 Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline

    Serious adverse events
    		 Placebo Steroid
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 16 (0.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    		 Placebo Steroid
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    0 / 14 (0.00%)
    4 / 16 (25.00%)
    Gastrointestinal disorders
    Nausea
    Additional description: Mild nausea and stomach upset
         subjects affected / exposed
    0 / 14 (0.00%)
    4 / 16 (25.00%)
         occurrences all number
    0
    4

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references
    http://www.ncbi.nlm.nih.gov/pubmed/20299628
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 09:36:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA